Skip to main content

CORRECTION article

Front. Pharmacol., 12 April 2022
Sec. Ethnopharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.896418
This article is part of the Research Topic Bone and Cartilage Diseases – The Role and Potential of Natural Products View all 19 articles

Corrigendum: The Therapeutic Effect of Huo Xue Tong Luo Capsules in Association Research Circulation Osseous (ARCO) Stage II Osteonecrosis of the Femoral Head: A Clinical Study With an Average Follow-up Period of 7.95 Years

This article is a correction to:

  1. The Therapeutic Effect of Huo Xue Tong Luo Capsules in Association Research Circulation Osseous (ARCO) Stage II Osteonecrosis of the Femoral Head: A Clinical Study With an Average Follow-up Period of 7.95 Years

    1. Read original article
Xiao-Ming He,&#x;Xiao-Ming He1,2†Min-Cong He,&#x;Min-Cong He1,2†Peng Yang,Peng Yang1,2Qing-Wen Zhang,Qing-Wen Zhang1,2Zhen-Qiu ChenZhen-Qiu Chen3Wei He, Wei He1,2*Qiu-Shi Wei, Qiu-Shi Wei1,2*
  • 1Guangdong Research Institute for Orthopedics and Traumatology of Chinese Medicine, Guangzhou, China
  • 2Joint Center, The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
  • 3The Third Orthopaedic Region, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

A Corrigendum on
The Therapeutic Effect of Huo Xue Tong Luo Capsules in Association Research Circulation Osseous (ARCO) Stage II Osteonecrosis of the Femoral Head: A Clinical Study With an Average Follow-up Period of 7.95 Years

by He, X.-M., He, M.-C., Yang, P., Zhang, Q.-W., Chen, Z.-Q., He, W., and Wei, Q.-S. (2021). Front. Pharmacol. 12:773758. doi:10.3389/fphar.2021.773758

In the published article, there is an error in the clinical trial registry number and the URL of Clinical Trial Registration. The correct Clinical Trial Registry details are “http://www.chictr.org.cn/showproj.aspx?proj=10829, ChiCTR-OPC-15007030”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: osteonecrosis of femoral head, ARCO stage II, therapeutic effect, risk factor, huo xue tong luo

Citation: He X-, He M-, Yang P, Zhang Q-, Chen Z-, He W and Wei Q- (2022) Corrigendum: The Therapeutic Effect of Huo Xue Tong Luo Capsules in Association Research Circulation Osseous (ARCO) Stage II Osteonecrosis of the Femoral Head: A Clinical Study With an Average Follow-up Period of 7.95 Years. Front. Pharmacol. 13:896418. doi: 10.3389/fphar.2022.896418

Received: 15 March 2022; Accepted: 16 March 2022;
Published: 12 April 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 He, He, Yang, Zhang, Chen, He and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wei He, hw13802516062@163.com; Qiu-Shi Wei, weiqshi@126.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.